NeurologyLive® Friday 5 — July 5, 2024

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Assessing Long-Term Benefit of Eptinezumab for Chronic Migraine: Amaal Starling, MD, FAHS, FAAN

The associate professor of neurology at Mayo Clinic College of Medicine discussed findings from a post-hoc analysis of the phase 3 PREVAIL study presented at AHS 2024 assessing eptinezumab in patients with chronic migraine. [WATCH TIME: 4 minutes]

2: Diagnosing Parkinson Disease and Other Synucleinopathies Through Syn-One Test: Sameea Husain-Wilson, DO

The neurologist and director of movement disorder neurology at the Marcus Neuroscience Institute provided an in-depth explanation of how the Syn-One test is used to help detect patients with Parkinson disease and related disorders. [WATCH TIME: 5 minutes]

3: Treatments Approved for Treatment of Spinal Muscular Atrophy

Key opinion leaders (KOLs) examine the mechanisms of action and other pertinent information regarding FDA-approved treatments for spinal muscular atrophy (SMA), sharing their perspectives on these therapies with a particular focus on the various modes of administration.

4: The Importance of Open Communication in Patient Care: Kelly Papesh, DNP, APRN, FNP-BC

The executive director of the Association of Movement Disorder Advanced Practice Providers discussed how effective patient care in movement disorders can lead to better management and treatment outcomes. [WATCH TIME: 4 minutes]

5: Importance of Telehealth Services for the MS Population

Bryant Robinson, the senior manager of government relations at the National MS Society, discussed how telehealth access has become vital for patients with multiple sclerosis who often lack nearby specialist care.